Hostname: page-component-76fb5796d-vvkck Total loading time: 0 Render date: 2024-04-28T00:48:46.263Z Has data issue: false hasContentIssue false
  • English
  • Français

Long-term effects of high-dose zidovudine treatment on neuropsychological performance in mildly symptomatic HIV-positive patients: Results of a randomized, double-blind, placebo-controlled investigation

Published online by Cambridge University Press:  09 February 2001

ANTOLIN M. LLORENTE ,
WILFRED G. VAN GORP ,
MARTIN J. STERN ,
LANCE GEORGE ,
PAUL SATZ ,
THOMAS D. MARCOTTE ,
GILBERT M. CALVILLO  and
CHARLES H. HINKIN
ANTOLIN M. LLORENTE
Affiliation:
Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles School of Medicine, Los Angeles, CA 90024
WILFRED G. VAN GORP
Affiliation:
Weill Medical College, Cornell University, New York, NY 10065
MARTIN J. STERN
Affiliation:
Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles School of Medicine, Los Angeles, CA 90024
LANCE GEORGE
Affiliation:
Veteran Affairs Medical Center, West Los Angeles, CA
PAUL SATZ
Affiliation:
Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles School of Medicine, Los Angeles, CA 90024
THOMAS D. MARCOTTE
Affiliation:
Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles School of Medicine, Los Angeles, CA 90024
GILBERT M. CALVILLO
Affiliation:
Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles School of Medicine, Los Angeles, CA 90024
CHARLES H. HINKIN
Affiliation:
Veteran Affairs Medical Center, West Los Angeles, CA
Get access Rights & Permissions [Opens in a new window]

Abstract

This study examined the treatment outcome of high-dose (1500 mg/day) zidovudine (AZT) on neuropsychological (NP) functioning (Trailmaking Test A & B, WAIS-R Digit Symbol, and Rey Auditory Verbal Learning Test) across a 12-month period in mildly symptomatic HIV-1 seropositive men (n = 46 at entry) enrolled in a randomized, double-blind, placebo-controlled trial (VA Cooperative Studies Program #298). Neither short-term (0–6 months) nor long-term (0–12 months) AZT administration revealed enhancement in NP performance. The results suggest that, although AZT may afford patients prophylactic benefits, protracted high-dose AZT treatment does not improve NP functioning in mildly symptomatic HIV-positive individuals. (JINS, 2001, 7, 27–32)

Keywords

HIV-1Prolonged AZT administrationNeuropsychological outcome
Type
Research Article
Information
Journal of the International Neuropsychological Society , Volume 7 , Issue 1 , January 2001 , pp. 27 - 32
Copyright
© 2001 The International Neuropsychological Society

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)